title: Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
abstract: Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for metastatic melanoma has shown objective response rates as high as 72%. The successful application of this therapy requires the selection of unique tumor-reactive lymphocyte cultures for each patient. This is a technically and logistically difficult undertaking, and patients who do not have tumor-reactive TIL are not considered eligible for treatment. To simplify the methods of TIL generation and extend TIL-based immunotherapy to additional patients, methods were developed to use unselected, minimally cultured ("young") TIL. Young TIL cultures contain a variable number of CD8(+), CD4(+), and CD3(-)CD56(+) natural killer cells. In this study we retrospectively investigated a role for these subsets in the clinical outcome of patients treated with TIL derived from selected microcultures. This analysis demonstrated a suggestive but nonsignificant association between the number of CD8(+) cells administered and tumor regression. We therefore investigated the feasibility of selecting CD8(+) cells from young TIL cultures for ACT therapy. The available methods for clinical scale CD8(+) enrichment proved inadequate for TIL, so an optimized CD8(+) enrichment method was developed and is reported here. We observed that CD8 (+)enrichment of some TIL cultures revealed in vitro tumor recognition that was not evident in bulk culture, and an improved in vitro recognition of tumor in other TIL cultures. In addition, the enriched CD8(+) young TIL expanded more reliably and predictably in rapid expansions than the bulk TIL. Thus, optimized CD8(+) selection combines the benefits of antigen-selected TIL and young TIL for generating lymphocyte cultures for ACT, and should be evaluated in cell transfer therapy protocols.
authors.affiliation: Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA. prietop@mail.nih.gov
authors.forename: Peter A
authors.initials: PA
authors.lastname: Prieto
authors.forename: Katherine H
authors.initials: KH
authors.lastname: Durflinger
authors.forename: John R
authors.initials: JR
authors.lastname: Wunderlich
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: Mark E
authors.initials: ME
authors.lastname: Dudley
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005434:Flow Cytometry; D015789:HLA-A2 Antigen / Q000378:metabolism; D006801:Humans; D018189:Immunomagnetic Separation; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000378:metabolism; D007519:Isoantigens / Q000276:immunology; D008213:Lymphocyte Activation; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology / Q000378:metabolism* / Q000473:pathology / Q000637:transplantation; D008545:Melanoma
chemical_list: D000951:Antigens, Neoplasm; D015789:HLA-A2 Antigen; C531098:HNA-4A antigen; D007519:Isoantigens; D007371:Interferon-gamma
references.citation: J Immunol Methods. 1990 Apr 17;128(2):189-201
references.pmid: 1691237
references.citation: Science. 2002 Oct 25;298(5594):850-4
references.pmid: 12242449
references.citation: Gastroenterology. 2009 Oct;137(4):1270-9
references.pmid: 19577568
references.citation: J Immunother. 2005 Jul-Aug;28(4):403-11
references.pmid: 16000960
references.citation: J Immunother. 2003 Jul-Aug;26(4):332-42
references.pmid: 12843795
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7
references.pmid: 12826605
references.citation: Cancer Treat Rev. 2008 Apr;34(2):145-56
references.pmid: 18077098
references.citation: Clin Cancer Res. 2008 Aug 15;14(16):5166-72
references.pmid: 18698034
references.citation: Clin Cancer Res. 2008 Sep 1;14(17):5610-8
references.pmid: 18765555
references.citation: J Immunother. 2009 May;32(4):415-23
references.pmid: 19342963
references.citation: J Immunol. 2005 Oct 1;175(7):4797-805
references.pmid: 16177129
references.citation: Mol Syst Biol. 2009;5:265
references.pmid: 19401677
references.citation: Cancer Immunol Immunother. 2008 May;57(5):623-34
references.pmid: 17899077
references.citation: J Immunol. 2006 Nov 1;177(9):6527-39
references.pmid: 17056585
references.citation: J Immunother. 2007 May-Jun;30(4):438-47
references.pmid: 17457218
references.citation: J Immunother. 2008 Oct;31(8):742-51
references.pmid: 18779745
references.citation: Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
references.pmid: 12427970
references.citation: Semin Oncol. 2007 Dec;34(6):532-45
references.pmid: 18083377
references.citation: Nat Med. 2004 Sep;10(9):942-9
references.pmid: 15322536
references.citation: Blood. 2006 Nov 1;108(9):2942-9
references.pmid: 16835376
references.citation: Eur J Cancer. 2009 Aug;45(12):2123-31
references.pmid: 19398324
references.citation: Blood. 2008 Dec 15;112(13):4953-60
references.pmid: 18820132
references.citation: Blood. 2008 Jul 15;112(2):362-73
references.pmid: 18354038
references.citation: Blood Cells Mol Dis. 2008 Jan-Feb;40(1):63-7
references.pmid: 17869548
references.citation: Curr Opin Immunol. 2009 Apr;21(2):233-40
references.pmid: 19304471
references.citation: Annu Rev Immunol. 2009;27:485-517
references.pmid: 19132915
references.citation: Hum Gene Ther. 2005 Apr;16(4):457-72
references.pmid: 15871677
references.citation: Cancer Immunol Immunother. 2009 May;58(5):823-30
references.pmid: 19198837
references.citation: J Immunother. 2002 May-Jun;25(3):243-51
references.pmid: 12000866
references.citation: J Immunol. 2006 Nov 1;177(9):6548-59
references.pmid: 17056587
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5060-9
references.pmid: 17075125
references.citation: Science. 2006 Oct 6;314(5796):126-9
references.pmid: 16946036
references.citation: Br J Haematol. 2006 Jul;134(1):64-76
references.pmid: 16803570
references.citation: Blood. 1998 Apr 15;91(8):2925-34
references.pmid: 9531603
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5233-9
references.pmid: 18809613
references.citation: J Immunother. 2001 Jul-Aug;24(4):363-73
references.pmid: 11565838
references.citation: J Immunol. 2005 Mar 1;174(5):2591-601
references.pmid: 15728465
references.citation: N Engl J Med. 2008 Jun 19;358(25):2698-703
references.pmid: 18565862